Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments

A.M.H. Krebber, L.M. Buffart, G. Kleijn, I.C. Riepma, R. de Bree, C.R. Leemans, A. Becker, J. Brug, A. van Straten, P. Cuijpers, I.M. Verdonck-de Leeuw

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Objective We aimed to investigate the prevalence of depression in cancer patients assessed by diagnostic interviews and self-report instruments, and to study differences in prevalence between type of instrument, type of cancer and treatment phase. Methods A literature search was conducted in four databases to select studies on the prevalence of depression among adult cancer patients during or after treatment. A total of 211 studies met the inclusion criteria. Pooled mean prevalence of depression was calculated using Comprehensive Meta-Analysis. Results Hospital Anxiety and Depression Scale - depression subscale (HADS-D) ≥ 8, HADS-D ≥11, Center for Epidemiologic Studies ≥ 16, and (semi-)structured diagnostic interviews were used to define depression in 66, 53, 35 and 49 studies, respectively. Respective mean prevalence of depression was 17% (95% CI = 16-19%), 8% (95% CI = 7-9%), 24% (95% CI = 21-26%), and 13% (95% CI = 11-15%) (p < 0.001). Prevalence of depression ranged from 3% in patients with lung cancer to 31% in patients with cancer of the digestive tract, on the basis of diagnostic interviews. Prevalence of depression was highest during treatment 14% (95% CI = 11-17%), measured by diagnostic interviews, and 27% (95% CI = 25-30%), measured by self-report instruments. In the first year after diagnosis, prevalence of depression measured with diagnostic interviews and self-report instruments were 9% (95% CI = 7-11%) and 21% (95% CI = 19-24%), respectively, and they were 8% (95% CI = 5-12%) and 15% (95% CI = 13-17%) ≥ 1 year after diagnosis. Conclusions Pooled mean prevalence of depression in cancer patients ranged from 8% to 24% and differed by the type of instrument, type of cancer and treatment phase. Future prospective studies should disentangle whether differences in prevalence of depression are caused by differences in the type of instrument, type of cancer or treatment phase. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.
Original languageEnglish
Pages (from-to)121-130
JournalPsycho-Oncology
Volume23
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Self Report
Meta-Analysis
Interviews
Depression
Neoplasms
Nuclear Family
Anxiety
Therapeutics
Gastrointestinal Tract
Epidemiologic Studies
Lung Neoplasms
Cross-Sectional Studies
Databases
Prospective Studies

Cite this

Krebber, A.M.H. ; Buffart, L.M. ; Kleijn, G. ; Riepma, I.C. ; de Bree, R. ; Leemans, C.R. ; Becker, A. ; Brug, J. ; van Straten, A. ; Cuijpers, P. ; Verdonck-de Leeuw, I.M. / Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. In: Psycho-Oncology. 2014 ; Vol. 23, No. 2. pp. 121-130.
@article{571e9e358dc04ca9afe8142fbf076391,
title = "Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments",
abstract = "Objective We aimed to investigate the prevalence of depression in cancer patients assessed by diagnostic interviews and self-report instruments, and to study differences in prevalence between type of instrument, type of cancer and treatment phase. Methods A literature search was conducted in four databases to select studies on the prevalence of depression among adult cancer patients during or after treatment. A total of 211 studies met the inclusion criteria. Pooled mean prevalence of depression was calculated using Comprehensive Meta-Analysis. Results Hospital Anxiety and Depression Scale - depression subscale (HADS-D) ≥ 8, HADS-D ≥11, Center for Epidemiologic Studies ≥ 16, and (semi-)structured diagnostic interviews were used to define depression in 66, 53, 35 and 49 studies, respectively. Respective mean prevalence of depression was 17{\%} (95{\%} CI = 16-19{\%}), 8{\%} (95{\%} CI = 7-9{\%}), 24{\%} (95{\%} CI = 21-26{\%}), and 13{\%} (95{\%} CI = 11-15{\%}) (p < 0.001). Prevalence of depression ranged from 3{\%} in patients with lung cancer to 31{\%} in patients with cancer of the digestive tract, on the basis of diagnostic interviews. Prevalence of depression was highest during treatment 14{\%} (95{\%} CI = 11-17{\%}), measured by diagnostic interviews, and 27{\%} (95{\%} CI = 25-30{\%}), measured by self-report instruments. In the first year after diagnosis, prevalence of depression measured with diagnostic interviews and self-report instruments were 9{\%} (95{\%} CI = 7-11{\%}) and 21{\%} (95{\%} CI = 19-24{\%}), respectively, and they were 8{\%} (95{\%} CI = 5-12{\%}) and 15{\%} (95{\%} CI = 13-17{\%}) ≥ 1 year after diagnosis. Conclusions Pooled mean prevalence of depression in cancer patients ranged from 8{\%} to 24{\%} and differed by the type of instrument, type of cancer and treatment phase. Future prospective studies should disentangle whether differences in prevalence of depression are caused by differences in the type of instrument, type of cancer or treatment phase. {\circledC} 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd. {\circledC} 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.",
author = "A.M.H. Krebber and L.M. Buffart and G. Kleijn and I.C. Riepma and {de Bree}, R. and C.R. Leemans and A. Becker and J. Brug and {van Straten}, A. and P. Cuijpers and {Verdonck-de Leeuw}, I.M.",
year = "2014",
doi = "10.1002/pon.3409",
language = "English",
volume = "23",
pages = "121--130",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. / Krebber, A.M.H.; Buffart, L.M.; Kleijn, G.; Riepma, I.C.; de Bree, R.; Leemans, C.R.; Becker, A.; Brug, J.; van Straten, A.; Cuijpers, P.; Verdonck-de Leeuw, I.M.

In: Psycho-Oncology, Vol. 23, No. 2, 2014, p. 121-130.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments

AU - Krebber, A.M.H.

AU - Buffart, L.M.

AU - Kleijn, G.

AU - Riepma, I.C.

AU - de Bree, R.

AU - Leemans, C.R.

AU - Becker, A.

AU - Brug, J.

AU - van Straten, A.

AU - Cuijpers, P.

AU - Verdonck-de Leeuw, I.M.

PY - 2014

Y1 - 2014

N2 - Objective We aimed to investigate the prevalence of depression in cancer patients assessed by diagnostic interviews and self-report instruments, and to study differences in prevalence between type of instrument, type of cancer and treatment phase. Methods A literature search was conducted in four databases to select studies on the prevalence of depression among adult cancer patients during or after treatment. A total of 211 studies met the inclusion criteria. Pooled mean prevalence of depression was calculated using Comprehensive Meta-Analysis. Results Hospital Anxiety and Depression Scale - depression subscale (HADS-D) ≥ 8, HADS-D ≥11, Center for Epidemiologic Studies ≥ 16, and (semi-)structured diagnostic interviews were used to define depression in 66, 53, 35 and 49 studies, respectively. Respective mean prevalence of depression was 17% (95% CI = 16-19%), 8% (95% CI = 7-9%), 24% (95% CI = 21-26%), and 13% (95% CI = 11-15%) (p < 0.001). Prevalence of depression ranged from 3% in patients with lung cancer to 31% in patients with cancer of the digestive tract, on the basis of diagnostic interviews. Prevalence of depression was highest during treatment 14% (95% CI = 11-17%), measured by diagnostic interviews, and 27% (95% CI = 25-30%), measured by self-report instruments. In the first year after diagnosis, prevalence of depression measured with diagnostic interviews and self-report instruments were 9% (95% CI = 7-11%) and 21% (95% CI = 19-24%), respectively, and they were 8% (95% CI = 5-12%) and 15% (95% CI = 13-17%) ≥ 1 year after diagnosis. Conclusions Pooled mean prevalence of depression in cancer patients ranged from 8% to 24% and differed by the type of instrument, type of cancer and treatment phase. Future prospective studies should disentangle whether differences in prevalence of depression are caused by differences in the type of instrument, type of cancer or treatment phase. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.

AB - Objective We aimed to investigate the prevalence of depression in cancer patients assessed by diagnostic interviews and self-report instruments, and to study differences in prevalence between type of instrument, type of cancer and treatment phase. Methods A literature search was conducted in four databases to select studies on the prevalence of depression among adult cancer patients during or after treatment. A total of 211 studies met the inclusion criteria. Pooled mean prevalence of depression was calculated using Comprehensive Meta-Analysis. Results Hospital Anxiety and Depression Scale - depression subscale (HADS-D) ≥ 8, HADS-D ≥11, Center for Epidemiologic Studies ≥ 16, and (semi-)structured diagnostic interviews were used to define depression in 66, 53, 35 and 49 studies, respectively. Respective mean prevalence of depression was 17% (95% CI = 16-19%), 8% (95% CI = 7-9%), 24% (95% CI = 21-26%), and 13% (95% CI = 11-15%) (p < 0.001). Prevalence of depression ranged from 3% in patients with lung cancer to 31% in patients with cancer of the digestive tract, on the basis of diagnostic interviews. Prevalence of depression was highest during treatment 14% (95% CI = 11-17%), measured by diagnostic interviews, and 27% (95% CI = 25-30%), measured by self-report instruments. In the first year after diagnosis, prevalence of depression measured with diagnostic interviews and self-report instruments were 9% (95% CI = 7-11%) and 21% (95% CI = 19-24%), respectively, and they were 8% (95% CI = 5-12%) and 15% (95% CI = 13-17%) ≥ 1 year after diagnosis. Conclusions Pooled mean prevalence of depression in cancer patients ranged from 8% to 24% and differed by the type of instrument, type of cancer and treatment phase. Future prospective studies should disentangle whether differences in prevalence of depression are caused by differences in the type of instrument, type of cancer or treatment phase. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.

U2 - 10.1002/pon.3409

DO - 10.1002/pon.3409

M3 - Article

VL - 23

SP - 121

EP - 130

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 2

ER -